Presentation is loading. Please wait.

Presentation is loading. Please wait.

Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after.

Published byMiloslava Dušková Modified over 5 years ago

Similar presentations

Presentation on theme: "Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after."— Presentation transcript:

1 Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after surgery in kidney transplant recipients who were given enteric-coated formulation of mycophenolate sodiu... Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after surgery in kidney transplant recipients who were given enteric-coated formulation of mycophenolate sodium (EC-MPS; n = 12) or mycophenolate mofetil (MMF; n = 20). Dario Cattaneo et al. CJASN 2007;2: ©2007 by American Society of Nephrology

Download ppt "Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after."

Similar presentations

Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.

The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Volume 79, Issue 8, Pages (April 2011)

Volume 79, Issue 8, Pages (April 2011)
Immunosuppression in liver transplant recipients with renal impairment

Immunosuppression in liver transplant recipients with renal impairment
Conceptual model of the natural history of diabetic kidney disease.

Conceptual model of the natural history of diabetic kidney disease.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
Consolidated Standards of Reporting Trials diagram.

Consolidated Standards of Reporting Trials diagram.
Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.
Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.
Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Representative polyacrylamide/6% urea gels that demonstrate transferrin saturation (TSAT) for (A) a patient who was given the low-dosage (1.5 mg/kg) infusion.

Representative polyacrylamide/6% urea gels that demonstrate transferrin saturation (TSAT) for (A) a patient who was given the low-dosage (1.5 mg/kg) infusion.

Similar presentations

Ads by Google